Knuff & Co LLC Raises Holdings in Novo Nordisk A/S $NVO

Knuff & Co LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 99.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 255,024 shares of the company’s stock after purchasing an additional 127,105 shares during the quarter. Novo Nordisk A/S makes up approximately 4.1% of Knuff & Co LLC’s portfolio, making the stock its 5th largest position. Knuff & Co LLC’s holdings in Novo Nordisk A/S were worth $14,151,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Beacon Financial Group grew its holdings in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the period. Kavar Capital Partners Group LLC raised its holdings in Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after purchasing an additional 200 shares during the period. SeaBridge Investment Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 5.7% during the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after acquiring an additional 200 shares in the last quarter. Joel Isaacson & Co. LLC increased its stake in Novo Nordisk A/S by 1.0% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after buying an additional 200 shares during the period. Finally, Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 2.0%

Shares of NVO stock opened at $38.04 on Friday. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $82.57. The stock’s fifty day simple moving average is $50.43 and its 200 day simple moving average is $51.92. The firm has a market capitalization of $169.83 billion, a P/E ratio of 10.96 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: WHO Foundation partnership expands Novo Nordisk’s global public‑health footprint and could support long‑term demand and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health With Valuation Story
• Positive Sentiment: Hims & Hers telehealth deal aims to broaden access to FDA‑approved GLP‑1s (Ozempic/Wegovy) and could help convert patients from compounded alternatives to branded products, supporting volume over time. Can Novo Nordisk’s Hims & Hers Deal Revive Its GLP‑1 Momentum?
• Neutral Sentiment: Zacks upgraded Novo from “strong sell” to “hold,” reducing immediate downside from the analyst side but not restoring bullish conviction. Zacks Upgrade
• Neutral Sentiment: Broad healthcare weakness is pressuring shares alongside company‑specific headlines; sector declines are a background headwind. Sector Update: Health Care Stocks Retreat
• Neutral Sentiment: Annual results from Novo Holdings (the controlling investor) show investment returns but also highlight sensitivity of its balance sheet to NVO’s share moves. This is context for ownership/market structure, not immediate company fundamentals. Novo Holdings Announces 2025 Annual Results
• Negative Sentiment: FDA issued a warning over unreported semaglutide safety events — this regulatory scrutiny is the primary catalyst for the recent sharp sell‑off and raises near‑term legal and compliance risk. FDA Issues Warning to Novo Nordisk
• Negative Sentiment: Market reaction to the FDA notice has been extreme in short windows — some reports cite very large intraday moves — amplifying volatility and momentum selling. Stock Falls After FDA Warning
• Negative Sentiment: Analysts have cut ratings and price targets (TD Cowen and others), and the share price has subsequently traded lower after downgrades, increasing downside pressure. Analyst Downgrade Coverage
• Negative Sentiment: Pomerantz law firm opened an investor investigation, signaling potential litigation risk for investors and management distractions. Pomerantz Investor Alert
• Negative Sentiment: Controlling shareholder Novo Holdings has seen its reported asset value fall sharply because of the share decline, highlighting the broader financial and governance knock‑on effects of the drop. Stock Slump Hits Controlling Shareholder

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NVO shares. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Finally, Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research note on Tuesday, March 3rd. Four analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $49.93.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.